There are 398 resources available
57TiP - SOLTI-1910: Predicting olaparib sensitivity in patients with unresectable locally advanced/metastatic HER2-negative breast cancer with BRCA1/2, PALB2, RAD51C/D mutations or HRD by the RAD51 test: RADIOLA TRIAL
Presenter: Judith Balmana
Session: Poster Display session
62P - Outcomes of high-risk breast cancer (BC) patients from El Álamo IV registry and GEICAM adjuvant clinical trials
Presenter: Miguel Martin Jimenez
Session: Poster Display session
63P - Efficacy and safety results by menopausal status in monarchE: Adjuvant abemaciclib combined with endocrine therapy in patients with HR+, HER2- high-risk early breast cancer
Presenter: Nadia Harbeck
Session: Poster Display session
64P - Concomitant discontinuation of cardiovascular therapy and adjuvant hormone therapy in breast cancer patients
Presenter: Erwei Zeng
Session: Poster Display session
65P - Evaluation of survival outcome of adjuvant chemoradiotherapy compared to other treatment modalities stratified by tumor size in T1N0M0 triple negative breast cancer
Presenter: Asmaa Ellaithy
Session: Poster Display session
66P - Impact of MAF selection of patients for adjuvant bisphosphonate therapy and comparison with current clinical guidance.
Presenter: Robert Coleman
Session: Poster Display session
67P - Clinicopathologic features of breast cancer patients eligible for adjuvant abemaciclib
Presenter: Paolo Tarantino
Session: Poster Display session
68P - 20-year tamoxifen benefit in ER-positive/HER2-negative breast cancer patients in randomized clinical trials
Presenter: Huma Dar
Session: Poster Display session
69P - Impact of statin use on survival outcomes of patients with HER2-positive early breast cancer in the APHINITY trial
Presenter: Christian Maurer
Session: Poster Display session
70P - Factors influencing patient treatment decisions in early breast cancer (eBC): discrete choice experiment (DCE) findings
Presenter: Alessandra Gennari
Session: Poster Display session